Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway

Background: The major limitation of EGFR TKIs in EGFR-mutant lung cancer therapy is the development of acquired resistance. The underlying mechanisms remain unknown in about 30% of cases. NF-κB activation was encountered in the acquired resistance to EGFR TKIs. Unfortunately, none of NF-κB inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Wang, Tao, Hu, Mengdi, Zhang, Yali, Chen, Hongzhuan, Xu, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511631/
https://www.ncbi.nlm.nih.gov/pubmed/33014814
http://dx.doi.org/10.3389/fonc.2020.01605

Ejemplares similares

Ejemplares similares